title: Vetrabutine clorhydrate use in dystocic farrowings minimizes hemodynamic sequels in piglets.
abstract: The objective was to measure the effects of VC (a uterotonic drug with vasodilator effects) in eutocic and dystocic sows, on the acid-base balance and some vitality traits of piglets at birth. Farrowing was induced with prostaglandin F2α. Four groups of sows (20 sows/group) were monitored; Groups 1 and 2 were eutocic sows, whereas Groups 3 and 4 were dam-fetal dystocic sows. Groups 1 and 3 (control) were given saline, whereas Groups 2 and 4 were given VC im (1.66 mg/kg of body weight) after the first piglet was born. Piglets' physio-metabolic performance was monitored peripartum. Treatment with VC reduced (P<0.0001) the percentage of intrapartum stillbirths in sows either with eutocic (5.2 vs. 10.0%) and dystocic (7.6 vs. 16.7%) farrowings and increased (P<0.0001) the number of pigs born alive without any evidence of AFS (89.9 vs. 79.9%, eutocic and 81.6 vs. 65.2%, dystocic). In addition, for the group of pigs with no acute fetal suffering (AFS), VC treatment enhanced survival responses with a half point grater vitality score in Group 4; it also reduced the latency to first teat contact by 6 min (P<0.05) in both treated groups compared to controls; and it improved the condition of the pigs' umbilical cord, with more adhered (98 vs. 86% in eutocic and 88 vs. 80% in dystocic; P<0.05) and less ruptured cords. Moreover, VC reduced the severity of adverse physio-metabolic indicators and the acid-base balance of piglets with AFS at birth by lowering blood lactate (89.8 vs. 93.5 mmol/L in eutocic groups and 94.6 vs. 100.2 mmol/L in dystocic groups; P<0.05), PaCO2 and Ca2+, and by increasing blood pH, HCO3 and PaO2 levels (P<0.05).
authors.affiliation: Postgraduate Division of Animal Science and Health, Faculty of Veterinary and Animal Production, Universidad Nacional Autónoma de México, Mexico.
authors.forename: M
authors.initials: M
authors.lastname: González-Lozano
authors.forename: M E
authors.initials: ME
authors.lastname: Trujillo-Ortega
authors.forename: M
authors.initials: M
authors.lastname: Alonso-Spilsbury
authors.forename: A M
authors.initials: AM
authors.lastname: Rosales
authors.forename: R
authors.initials: R
authors.lastname: Ramírez-Necoechea
authors.forename: A
authors.initials: A
authors.lastname: González-Maciel
authors.forename: R
authors.initials: R
authors.lastname: Martínez-Rodríguez
authors.forename: M
authors.initials: M
authors.lastname: Becerril-Herrera
authors.forename: D
authors.initials: D
authors.lastname: Mota-Rojas
mesh_terms: D000136:Acid-Base Equilibrium / Q000187:drug effects*; D000818:Animals; D000831:Animals, Newborn; D001596:Benzylamines / Q000627:therapeutic use*; D004420:Dystocia / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D010120:Oxytocics / Q000627:therapeutic use*; D011247:Pregnancy; D050497:Stillbirth / Q000662:veterinary; D013552:Swine; D014470:Umbilical Cord
chemical_list: D001596:Benzylamines; D010120:Oxytocics; C551390:vetrabutin chlorhydrate